This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Sarepta's Risks Shouldn't Be Ignored

I worry that the absolute 78-meter decline in 6MWT for the placebo group at 36 weeks seems unusually rapid. A 2010 study published in Muscle and Nerve suggests somewhat slower progression -- less than 60 meters of decline -- at 52 weeks. Although this difference could be due to normal disease variability or patient differences, the late acceleration of progression in the placebo group is a red flag.

Feuerstein, in his last column on Sarepta, wants, justifiably, to see a correlation between 48-week dystrophin levels and clinical outcomes. I do too. Those data could eliminate my concern about this issue.

4. Sarepta's patent situation seems shaky. Prosensa has rights to patents, both in the U.S. and Europe, which appear to cover Sarepta's eteplirsen. In fact, Sarepta tried and failed to overturn Prosensa's European patent related to treatment of DMD through skipping of dystrophin exons 51 and 46. That's a concern. Although a weak patent estate won't impact Sarepta's data, it might temper eteplirsen's commercial potential.

5. Corporate red flags are a concern. I'm not crazy about Sarepta's recent name change and one-for-six reverse stock split, but those are forgivable offenses given potentially groundbreaking data. I'm far less sanguine about the June 2012 resignation of Chief Scientific Officer Dr. Peter Linsley. Although Dr. Linsley informed the company of his intent in mid-April, this should be considered a concern for two reasons. First, high-ranking executives rarely resign without any apparent reason on the cusp of positive data. Second, Sarepta never issued a press release about the change, instead choosing to disclose the information in an SEC Form 8-K. Although management briefly mentioned the change on the company's Q1 2012 call, investors seem to have missed it.

I'm not ready to declare eteplirsen a breakthrough, but it definitely appears promising. Given Sarepta's $230 million market capitalization and the obvious unmet medical need in DMD, I think the stock is a reasonable long position for biotech investors with a healthy appetite for risk. Nonetheless, I would keep the position on the smaller side since the roads of biotech can be unexpectedly bumpy.

Caveat emptor.

Disclosure: Sadeghi has no positions in any of the stocks mentioned in this article.

Follow Nathan Sadeghi-Nejad on Twitter.
Nathan Sadeghi-Nejad has 15 years experience as a professional health-care investor, most recently as a sector head for Highside Capital. He has worked on the sell side (with independent research boutiques Sturza's Medical Research and Avalon Research) and the buyside (at Kilkenny Capital prior to Highside). Sadeghi-Nejad is a graduate of Columbia University and lives in New York. You can follow him on Twitter @natesadeghi.
3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
GSK $42.91 0.00%
SRPT $14.19 0.00%
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs